The study rested on a deceptively simple observation about how previous research had approached the problem. Most imaging studies of people with isolated REM sleep behaviour disorder have examined one biomarker at a time, measuring, for example, dopamine transporter loss in the striatum, or cortical atrophy on structural MRI, or markers of brain inflammation. Such single-modality measures can indicate that a patient is on track to develop some form of neurodegenerative disease, but they generally cannot distinguish Parkinson’s disease from dementia with Lewy bodies, because both conditions involve overlapping pathology of the alpha-synuclein protein. The Danish-Spanish team reasoned that the key to phenotype-specific prediction might lie not in any single scan but in the relationships between multiple pathological processes measured simultaneously in the same brain.

To test this idea, the researchers recruited a well-characterised cohort of twenty-one patients with isolated REM sleep behaviour disorder and put them through an unusually comprehensive imaging protocol. Each patient received positron emission tomography scans with three different radioactive tracers, each designed to illuminate a distinct facet of brain biology. Fluorine-18 labelled DOPA PET quantified the integrity of the dopaminergic system, particularly the nigrostriatal pathways that degenerate in Parkinson’s disease. Carbon-11 labelled donepezil PET mapped cholinergic function, revealing the density of acetylcholine signalling, which is known to be profoundly disrupted in dementia with Lewy bodies and to underlie many of its cognitive and perceptual symptoms. Carbon-11 labelled PK11195 PET, meanwhile, served as a window onto neuroinflammation by binding to activated microglia, the brain’s resident immune cells, which become mobilised in response to ongoing neurodegenerative injury.

Alongside the PET examinations, each participant underwent structural magnetic resonance imaging to quantify grey matter volume across the cortex, as well as dynamic susceptibility contrast MRI, a technique that tracks a bolus of contrast agent moving through the cerebral vasculature. From these perfusion measurements the team extracted indices of microcirculatory dysregulation, capturing how well blood was being delivered and distributed through the brain’s smallest vessels. The inclusion of this microvascular dimension reflects a growing appreciation, championed in earlier work by co-author Leif Østergaard’s group in Aarhus, that capillary dysfunction may be an underappreciated contributor to neurodegenerative disease rather than a mere bystander.

The analytical centrepiece of the study was a multimodal adaptation of the scaled sub-profile model, a statistical framework originally developed to identify disease-related patterns of covariance in functional imaging data from patients with Parkinson’s disease. Rather than asking whether any single region or single tracer differed between patients, the method searches for spatially distributed networks across which the multiple imaging modalities co-vary together. In other words, it looks for brain regions where, across the cohort, dopaminergic loss, cholinergic decline, inflammation, atrophy and microvascular impairment rise and fall in a coordinated fashion. This approach transforms a collection of separate scans into a single integrated portrait of each patient’s brain, and it is precisely this integration that gave the study its predictive power.

What emerged was a coherent multimodal network converging on the medial occipito-parietal cortex, the posterior region of the brain encompassing the cuneus and adjacent parietal areas. Within this network, the same patients who showed high neuroinflammation also tended to show cholinergic dysfunction, grey matter atrophy and microcirculatory problems, all concentrated in the same posterior cortical territory. This convergence is biologically meaningful. The occipito-parietal cortex has long been implicated in the visual hallucinations, fluctuating cognition and visuospatial deficits that distinguish dementia with Lewy bodies from other dementias, and earlier studies by several of the same authors had already flagged cuneus atrophy as a harbinger of phenoconversion. The new findings suggest that this region is not merely one affected area among many but a genuine crossroads where multiple pathological processes meet.

The predictive result was the study’s most dramatic finding. When the team combined the multimodal occipito-parietal pattern with striatal fluorine-18 DOPA uptake, a measure of dopaminergic integrity in the basal ganglia, the composite measure specifically predicted conversion to dementia with Lewy bodies rather than to Parkinson’s disease. The strength of the association was expressed as a sub-distribution hazard ratio of 38.68, with a ninety-five percent confidence interval running from 7.545 to 198.3, and the effect survived statistical correction for age and disease duration. In practical terms, patients whose brains displayed the posterior cortical pathological signature together with striatal dopaminergic impairment were dramatically more likely to develop the dementing form of synucleinopathy, while those without it were more likely to convert to the motor-predominant Parkinsonian phenotype.

The implications for clinical practice and for drug development are considerable. Neuroprotective trials for Parkinson’s disease and for dementia with Lewy bodies have repeatedly been hampered by the inclusion of heterogeneous patient populations, in which participants destined for different clinical outcomes are lumped together, diluting any apparent treatment effect. A biomarker that can stratify prodromal patients by their likely conversion phenotype would allow trials to enrol more homogeneous cohorts, match experimental therapies to the disease process they are actually designed to slow, and interpret outcomes more cleanly. For patients themselves, knowing years in advance whether the likely future holds a movement disorder or a dementia could transform planning, monitoring and, eventually, the timing of interventions aimed at the earliest stages of disease.

The study also adds weight to a broader conceptual shift in how prodromal synucleinopathies are understood. Recent biological staging frameworks, including the SynNeurGe criteria for Parkinson’s disease and the integrated staging system for neuronal alpha-synuclein disease, have argued that diagnosis and prognosis should rest on biological markers rather than on clinical syndromes that appear only late in the disease course. The multimodal imaging profile described by Baun and colleagues fits squarely within this vision, offering a way to characterise the internal biology of prodromal disease rather than simply waiting for symptoms to declare themselves. It complements other emerging biomarkers, such as the detection of misfolded alpha-synuclein in cerebrospinal fluid by seed amplification assays, by adding spatial and mechanistic information that fluid biomarkers cannot provide.

Caveats remain, and the authors are careful about them. The cohort of twenty-one patients is small, and multimodal PET studies of this depth are expensive and technically demanding, which limits how readily the approach can be scaled to large populations. The supporting data are available only from the corresponding authors upon reasonable request, reflecting privacy constraints on the participants. Nevertheless, the consistency of the posterior cortical findings with a growing independent literature, including studies of cortical thickness, perfusion, metabolism and atrophy progression in the same patient population, lends credibility to the central conclusion. If future studies replicate the result in larger cohorts, the dream of telling a sleeping patient which disease awaits them, and of intervening before it arrives, will have moved a decisive step closer to the clinic.

Subject of Research: Multimodal PET-MRI biomarkers for predicting phenoconversion to dementia with Lewy bodies in isolated REM sleep behaviour disorder

Article Title: Multimodal PET–MRI profiling predicts dementia with Lewy bodies in isolated REM sleep behaviour disorder

Article References: Baun, A. M., Iranzo, A., Terkelsen, M. H., Hinz, R., Stokholm, M. G., Serradell, M., Svendsen, K. B., Garrido, A., Vilas, D., Møller, A., Gaig, C., Tolosa, E., Brooks, D. J., Borghammer, P., Eskildsen, S. F., & Pavese, N. (2026). Multimodal PET–MRI profiling predicts dementia with Lewy bodies in isolated REM sleep behaviour disorder. Journal of Neurology, 273(10), Article 635. https://doi.org/10.1007/s00415-026-14176-3

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14176-3

Keywords: REM sleep behaviour disorder, dementia with Lewy bodies, Parkinson's disease, PET imaging, MRI, neuroinflammation, cholinergic dysfunction, striatal dopamine, occipito-parietal cortex, biomarkers, neurodegeneration, alpha-synuclein

The scale of the problem the researchers set out to address is enormous. Parkinson’s disease is the second most common neurodegenerative disorder worldwide and the fastest-growing neurological condition in terms of prevalence, disability, and mortality. Driven by global population ageing, the number of people living with the disease has more than doubled over the past two decades and is projected to exceed 12 million by 2040. Sleep disturbances, including insomnia, excessive daytime sleepiness, REM sleep behaviour disorder, restless legs syndrome, and poor sleep quality, are consistently among the most prevalent and disabling of the disease’s non-motor symptoms, yet the pharmacological evidence base has remained fragmented across sleep phenotypes, drug classes, and outcome instruments.

The biology underlying these sleep problems is complex and multifactorial. Degeneration of dopaminergic and non-dopaminergic pathways, deposition of alpha-synuclein in brainstem and hypothalamic nuclei, disruption of circadian regulation, nocturnal motor symptoms, psychiatric comorbidities, autonomic dysfunction, and the adverse effects of antiparkinsonian medications may all contribute. This heterogeneity matters clinically, because different sleep phenotypes may respond to entirely different drugs: wake-promoting agents for daytime sleepiness, melatonergic compounds for circadian disruption, dopaminergic drugs for nocturnal motor interference with sleep, and sedative-hypnotics for insomnia. The new review, led by Jaquelini Betta Canever and colleagues at the Federal University of Santa Catarina in Brazil, is the first to synthesise the randomised trial evidence systematically across all of these phenotypes at once.

The trials included in the analysis spanned more than two decades, from 2002 to 2025, and were conducted in 14 countries across five continents. The pharmacological landscape they covered was remarkably broad. Chronobiotic agents, meaning melatonin and prolonged-release melatonin, were the most frequently evaluated class, appearing in seven trials at doses ranging from 2 to 10 milligrams. Wake-promoting agents and psychostimulants featured in seven trials, including modafinil, methylphenidate, the experimental modafinil-flecainide combination THN102, solriamfetol, and sodium oxybate. Dopaminergic receptor agonists were examined in five trials, including the rotigotine transdermal patch, apomorphine infusion, piribedil, and prolonged-release ropinirole. Single trials evaluated cannabidiol, zonisamide, clonazepam, eszopiclone, trazodone, 5-hydroxytryptophan, caffeine, homotaurine, the MAO-B inhibitors safinamide and rasagiline, and even a traditional nyctinastic herbs decoction.

The clearest signal emerged for overall sleep quality measured with the Pittsburgh Sleep Quality Index. Across six trials testing melatonin, modafinil, and rotigotine, pharmacological treatment produced a pooled mean difference of 2.66 points, with a 95 percent confidence interval of 1.63 to 3.69 and a p value below 0.001. The direction of benefit was consistent across all six contributing trials, and the magnitude approximates the minimal clinically important difference reported in comparable populations. Leave-one-out sensitivity analysis confirmed the result was highly robust: removing any single trial produced pooled estimates ranging from 2.20 to 3.11, all with confidence intervals entirely excluding the null. Subgroup analysis showed that melatonin preparations as a class exerted a consistent moderate benefit, with only moderate residual heterogeneity, while the rotigotine patch produced the single largest effect of any agent.

That rotigotine finding, however, comes with an important caveat that the authors flag explicitly. Rotigotine is primarily prescribed to treat the motor symptoms of Parkinson’s disease rather than sleep disturbance specifically, so part of the observed improvement in sleep quality scores may reflect secondary benefits of better nocturnal motor control, such as reduced nighttime akinesia, rigidity, and difficulty repositioning, rather than a direct sleep-specific pharmacological effect. The biologically plausible mechanism, involving D3 receptor activity in the basal ganglia and hypothalamus that could improve nocturnal sleep architecture, remains attractive, but the confound cannot be excluded with the available data.

For excessive daytime sleepiness, the picture was far less convincing. Six study arms from five trials, testing modafinil, methylphenidate, and melatonin, produced a pooled estimate on the Epworth Sleepiness Scale that pointed toward benefit but failed to reach statistical significance, with a mean difference of 1.75 and a confidence interval spanning zero. Heterogeneity was extreme at 91 percent, driven predominantly by a single small crossover trial from 2002 that was the only arm favouring placebo. When that influential outlier was removed in sensitivity analysis, the pooled estimate became statistically significant for the first time, suggesting the aggregate result was masked by a trial whose anomalous direction is consistent with carry-over effects from inadequate washout. Intriguingly, a subgroup analysis by treatment duration found that trials lasting more than four weeks showed a significant pooled benefit, while shorter trials did not, though the authors stress this rests on very few studies and should be regarded as hypothesis-generating rather than a dosing recommendation.

For insomnia symptoms and REM sleep behaviour disorder, the evidence collapsed under its own inconsistency. Three trials assessing insomnia with the Parkinson’s Disease Sleep Scale produced a directionally favourable but non-significant pooled estimate with 96 percent heterogeneity, reflecting pharmacologically distinct agents tested in substantially different populations. The REM sleep behaviour disorder analysis was limited to just two trials, zonisamide and safinamide, which produced directionally opposite results that nearly cancelled each other out, yielding a clinically uninformative pooled estimate with 99 percent heterogeneity. Compounding the problem, neither trial diagnosed the disorder using international classification criteria, and severity was inferred from a global Parkinson’s sleep scale rather than a dedicated, validated instrument. The authors therefore present these pooled estimates as exploratory only, emphasising narrative synthesis over the point estimates.

The methodological quality of the underlying trials emerged as a sobering thread throughout the analysis. Using the Cochrane Risk of Bias 2 tool, the reviewers judged only 5 of the 29 trials, or 17.2 percent, to be at low overall risk of bias, while 18 raised some concerns and 6 were classified as high risk. The main sources of concern were the randomisation process and missing outcome data. Applying the GRADE framework, the certainty of evidence ranged from low to very low across all outcome domains, meaning that even the statistically significant sleep quality finding should be interpreted with appropriate caution. Publication bias could not be formally excluded for any domain, since all meta-analyses contained fewer than the ten studies required for formal statistical testing, although the funnel plot for sleep quality offered tentative reassurance.

On safety, the review found no unexpected or severe signals beyond those already characterised in the broader pharmacological literature, though this reassurance is bounded by limited trial durations of two to 24 weeks and 1,913 total participants. Dopaminergic receptor agonists carried the highest rates of any adverse event, with ropinirole reaching 74.3 percent in one trial, consistent with known class effects such as nausea, orthostatic hypotension, and impulse control disorders. Adverse event rates for melatonin ranged from zero to 88.6 percent across studies, a striking spread the authors attribute to differences in how events were ascertained rather than to genuine toxicity. Treatment discontinuation rates were generally low, with cannabidiol showing the highest rate among agents with multiple contributing studies at 15 percent. The authors call for future trials with prospective phenotypic stratification, harmonised primary outcome instruments, head-to-head comparisons between drug classes, polysomnographic endpoints alongside patient-reported outcomes, and standardised safety reporting frameworks, so that the next generation of evidence can finally translate into reliable, clinically actionable guidance for the millions of Parkinson’s patients whose nights are currently governed by trial and error.

Subject of Research: Pharmacological treatment of sleep disorder phenotypes in Parkinson's disease

Article Title: Pharmacological treatment of sleep disorder phenotypes in Parkinson’s disease: a systematic review and meta-analysis of randomised controlled trials

Article References: Pharmacological treatment of sleep disorder phenotypes in Parkinson’s disease: a systematic review and meta-analysis of randomised controlled trials. (n.d.). https://doi.org/10.1007/s00415-026-14158-5

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14158-5

Keywords: Parkinson's disease, sleep disorders, meta-analysis, melatonin, excessive daytime sleepiness, REM sleep behaviour disorder, insomnia, rotigotine, randomised controlled trials, sleep quality, neuropharmacology, systematic review